A Retrospective, multicentre study to assess the risk of sinusoidal obstruction syndrome (SOS) associated with Gemtuzumab Ozogamicin treatment prior to Allogenic stem cell transplantation in patients with Acute myeloid leukemia

Trial Profile

A Retrospective, multicentre study to assess the risk of sinusoidal obstruction syndrome (SOS) associated with Gemtuzumab Ozogamicin treatment prior to Allogenic stem cell transplantation in patients with Acute myeloid leukemia

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jan 2017

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Jan 2017 New trial record
    • 16 Jan 2017 Results published in the Bone Marrow Transplantation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top